LYXUMIA

This brand name is authorized in Austria, Brazil, Cyprus, Estonia, Spain, Finland, Hong Kong, Ireland, Japan, Lithuania, Netherlands, Poland, Romania, Singapore, Turkey, United Kingdom

Active ingredients

The drug LYXUMIA contains one active pharmaceutical ingredient (API):

1 Lixisenatide UNII 74O62BB01U - LIXISENATIDE

Lixisenatide is a selective GLP-1 receptor agonist. The GLP-1 receptor is the target for native GLP-1, an endogenous incretin hormone that potentiates glucose-dependent insulin secretion from the pancreatic beta cells. Lixisenatide stimulates insulin secretion when blood glucose is increased but not at normoglycaemia, which limits the risk of hypoglycaemia. In parallel, glucagon secretion is suppressed. In case of hypoglycaemia, the rescue mechanism of glucagon secretion is preserved. Read about Lixisenatide

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
LYXUMIA Solution for injection	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
A10BJ03		A Alimentary tract and metabolism → A10 Drugs used in diabetes → A10B Blood glucose lowering drugs, excl. insulins → A10BJ Glucagon-like peptide-1 (GLP-1) analogues
Discover more medicines within A10BJ03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 502813120065802, 502813120066002, 576720080085017, 576720080085117
Country: EE	Ravimiamet	Identifier(s): 1607206, 1607217, 1607228, 1607239, 1607240
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 12811001, 12811003
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 376568, 464765
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 219411, 219413, 219416, 219538
Country: HK	Department of Health Drug Office	Identifier(s): 62767
Country: JP	医薬品医療機器総合機構	Identifier(s): 2499415G1024
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1069321, 1069353, 1069354, 1069355, 1069356
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 117854, 117862
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100040433, 100292821, 100292838
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W59971001, W59971002, W59971003
Country: SG	Health Sciences Authority	Identifier(s): 14653P, 14654P, 14655P
Country: TR	İlaç ve Tıbbi Cihaz Kurumu	Identifier(s): 8699809950818, 8699809950825, 8699809950832, 8699809950849